CAS 70-51-9

Deferoxamina

Descrição:

Deferoxamina é um agente quelante usado principalmente no tratamento de condições de sobrecarga de ferro, como aquelas resultantes de transfusões de sangue repetidas em pacientes com condições como talassemia ou doença falciforme. É um ligante hexadentado, o que significa que pode formar múltiplas ligações com um único íon metálico, ligando-se especificamente a íons férricos (Fe³⁺) para facilitar sua excreção do corpo. Deferoxamina é tipicamente administrado por vias subcutâneas ou intravenosas, pois é mal absorvido pelo trato gastrointestinal. O composto é caracterizado por sua capacidade de formar complexos estáveis com o ferro, o que ajuda a reduzir a toxicidade do ferro e prevenir danos aos órgãos. Além de seus usos terapêuticos, Deferoxamina tem sido estudado por suas potenciais propriedades antioxidantes e seu papel em várias aplicações de pesquisa. Sua estrutura química inclui um grupo funcional ácido hidroxâmico, que é crucial para suas propriedades de quelante. No geral, Deferoxamina desempenha um papel vital no manejo da sobrecarga de ferro e na melhoria dos resultados dos pacientes em distúrbios hematológicos específicos.

Fórmula: C₂₅H₄₈N₆O₈

InChI: InChI=1/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)

Chave InChI: InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N

SMILES: C(CCC(NCCCCCN(C(C)=O)O)=O)(N(CCCCCNC(CCC(N(CCCCCN)O)=O)=O)O)=O

Sinónimos:

• 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-
• 30-Amino-3,14,25-trihydroxy-3,9,14,20,25 pentaazatriacontane-2,10,13,21,24-pentaone
• Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-
• Butanediamide, N⁴-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxy-
• Deferoxamin
• Deferoxamina
• Deferoxamine B
• Deferriferrioxamine B
• Deferrioxamine
• Deferrioxamine B
• Desferan
• Desferex
• Desferin
• Desferioxamine B
• Desferoxime
• Desferrin
• Desferrioxamine
• Desferrioxamine B
• Dfo-B
• N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide
• N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic acid
• N⁴-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxybutanediamide
• Nsc 527604
• N′-[5-[Acetyl(hydroxy)amino]pentyl]-N-7-[5-([4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl]amino)pentyl]-N-hydroxysuccinamide
• Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-
• N4-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxybutanediamide
• Butanediamide, N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-
• n-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(n-hydroxy
• ba-33112
• deferoxaminum
• n’-[5-[[4-[[5-(acetylhydroxamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pen
• N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide
• butanediamide,n’-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)h
• deferoxamideb
• entaone
• 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,
• acetamido)pentyl]carbamoyl]propionohydroxamicacid
• N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-keto-butanoyl]amino]pentyl]-N-hydroxy-succinamide
• n-benzoyl-ferrioxamine
• Deferoxamine USP/EP/BP
• taone
• 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihyd
• N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobuta
• deferoxamine
• deferoxamineb
• desferrioxamineb
• 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trih
• ba-29837
• tyl]-n-(5-aminopentyl)-n-hydroxybutanediamide
• deferrioxamineb
• desferriferrioxaminb
• 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-p
• 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pen
• ba33112
• N'-{5-[ACETYL(HYDROXY)AMINO]PENTYL}-N-[5-({4-[(5-AMINOPENTYL)(HYDROXY)AMINO]-4-OXOBUTANOYL}AMINO)PENTYL]-N-HYDROXYSUCCINAMIDE
• N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide
• N-[5-[[4-[5-azanylpentyl(hydroxy)amino]-4-oxo-butanoyl]amino]pentyl]-N'-[5-[ethanoyl(hydroxy)amino]pentyl]-N-hydroxy-butanediamide
• 22-tetraazaheptaeicosane
• n-benzoylferrioxamineb
• DESFEROXAMINE
• DESFERROXAMINE
• desferral
• ydroxyamino)pentyl)-n-(5-aminopentyl)-n-hydroxy-
• dfoa

Deferoxamine Mesylate

CAS: 138-14-7, 70-51-9

Fórmula: C₂₅H₄₈N₆O₈·CH₄O₃S

Pureza: >97.0%(T)(HPLC)

Cor e Forma: White to Light yellow powder to crystal

Peso molecular: 656.79

Ref: 3B-D4245

Deferoxamine

CAS: 70-51-9

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine has antioxidant, anti-proliferative and anti-tumor activities. High-Quality, Low-Cost!

Fórmula: C₂₅H₄₈N₆O₈

Pureza: 99.66% - 99.97%

Cor e Forma: Solid

Peso molecular: 560.68

Ref: TM-T124358

N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide

CAS: 70-51-9

Fórmula: C₂₅H₄₈N₆O₈

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 560.6840

Ref: IN-DA005IGL

Deferoxamine

CAS: 70-51-9

Deferoxamine

Pureza: ≥98%

Peso molecular: 560.68g/mol

Ref: 54-BUP04137

Deferoxamine

CAS: 70-51-9

Deferoxamine is a polymerase chain inhibitor that binds to the folate receptor, a protein on the surface of cells. It is used as an antidote to poisoning by iron, arsenic, and other metals. Deferoxamine also has antioxidant properties and can be used in the treatment of iron overload diseases such as hemochromatosis. Deferoxamine-iron complexes are excreted in the urine, which may be useful for monitoring iron homeostasis. This drug is not active against squamous cell carcinomas or wild-type strains of bacteria that do not have a functional folate receptor.

Fórmula: C₂₅H₄₈N₆O₈

Pureza: Min. 95%

Cor e Forma: Solid

Peso molecular: 560.68 g/mol

Ref: 3D-FD46531